FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 9.2% in July
FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 9.2% in July
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 4,950,000 shares, a decrease of 9.2% from the July 15th total of 5,450,000 shares. Currently, 5.8% of the company's shares are sold short. Based on an average daily volume of 971,600 shares, the short-interest ratio is presently 5.1 days.
FibroGen,Inc.(纳斯达克:FDEN-GET评级)看到空头股数在7月份大幅下降。截至7月31日,空头股数共有495万股,较7月15日的545万股减少了9.2%。目前,该公司5.8%的股票被卖空。以日均成交量97.16万股计算,目前短息比率为5.1天。
FibroGen Stock Performance
FibroGen股票表现
Shares of FGEN remained flat at $14.44 during midday trading on Wednesday. 11,717 shares of the stock were exchanged, compared to its average volume of 653,054. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50 day simple moving average is $11.91 and its 200 day simple moving average is $11.98. FibroGen has a 52 week low of $7.81 and a 52 week high of $16.91.
在周三午盘交易中,fgen的股价持平于14.44美元。该股成交量为11,717股,而平均成交量为653,054股。该股市值13.5亿美元,市盈率为-6.05倍,贝塔系数为0.87。该公司的50日简单移动均线切入位为11.91美元,200日简单移动均线切入位为11.98美元。FibroGen的52周低点为7.81美元,52周高位为16.91美元。
FibroGen (NASDAQ:FGEN – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same quarter in the previous year, the business earned ($1.45) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. As a group, analysts anticipate that FibroGen will post -3 earnings per share for the current fiscal year.
FibroGen(纳斯达克:FDEN-GET评级)上一次公布季度收益是在8月8日星期一。这家生物制药公司公布了该季度每股收益(0.78美元),比分析师普遍预期的(0.94美元)高出0.16美元。FibroGen的净资产回报率为负100.51%,净利润率为负83.64%。该公司本季度营收为2981万美元,而市场普遍预期为3615万美元。去年同期,该业务实现每股收益(1.45美元)。与去年同期相比,该业务的收入增长了22.3%。作为一个整体,分析师预计FibroGen将公布本财年的每股收益为3美元。
Hedge Funds Weigh In On FibroGen
对冲基金对FibroGen的看法
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several equities analysts have recently issued reports on FGEN shares. Cowen boosted their price target on shares of FibroGen to $14.00 in a report on Monday. The Goldman Sachs Group lowered their target price on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th. Finally, StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th.
几位股票分析师最近发布了关于fgen股票的报告。考恩在周一的一份报告中将FibroGen的股价目标上调至14.00美元。在5月24日周二的一份报告中,高盛夫妇将FibroGen的目标价从9.00美元下调至8.00美元,并对该公司设定了“卖出”评级。最后,StockNews.com在8月10日星期三的一份报告中将FibroGen的股票评级从“买入”下调至“持有”。
FibroGen Company Profile
FibroGen公司简介
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物制药公司,发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat,该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发,并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- Lowe‘s在第二季度零售报告中脱颖而出
- 安捷伦科技对Illumina证明了自己的价值
- 塔吉特的业绩上限零售类股的上行潜力
- 这3只电子游戏股票现在还在玩吗?
- 2辆长期电动汽车的交易价格低于20美元
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。